Summary
Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)
- The report reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Attention Deficit Hyperactivity Disorder (ADHD) therapeutics and enlists all their major and minor projects
- The report assesses Attention Deficit Hyperactivity Disorder (ADHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Alcobra Ltd
Amarantus Bioscience Holdings, Inc.
APeT Holding BV
Arbor Pharmaceuticals, LLC
BCWorld Pharm Co. Ltd.
BioLite, Inc.
Collegium Pharmaceutical, Inc.
Curemark, LLC
DURECT Corporation
Egalet Corporation
Eli Lilly and Company
Ensysce Biosciences Inc.
H. Lundbeck A/S
Heptares Therapeutics Limited
Highland Therapeutics, Inc.
Integrative Research Laboratories Sweden AB
Intra-Cellular Therapies, Inc.
INVENT Pharmaceuticals, Inc.
KemPharm, Inc.
Luc Therapeutics, Inc.
Medgenics, Inc.
Merck & Co., Inc.
Neos Therapeutics, Inc.
NeuroDerm Ltd.
Neurovance, Inc.
NLS Pharma Group
Noven Pharmaceuticals, Inc.
P2D Bioscience
Polleo Pharma Limited
Reviva Pharmaceuticals Inc.
Shire Plc
Sunovion Pharmaceuticals Inc.
Supernus Pharmaceuticals, Inc.
Taisho Pharmaceutical Co., Ltd.
Taisho Pharmaceutical Holdings Co., Ltd.
TRImaran Pharma, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Attention Deficit Hyperactivity Disorder (ADHD) Overview 9
Therapeutics Development 10
Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview 10
Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis 11
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies 12
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes 16
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies 21
Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes 25
Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development 26
Alcobra Ltd 26
Amarantus Bioscience Holdings, Inc. 27
APeT Holding BV 28
Arbor Pharmaceuticals, LLC 29
BCWorld Pharm Co. Ltd. 30
BioLite, Inc. 31
Collegium Pharmaceutical, Inc. 32
Curemark, LLC 33
DURECT Corporation 34
Egalet Corporation 35
Eli Lilly and Company 36
Ensysce Biosciences Inc. 37
H. Lundbeck A/S 38
Heptares Therapeutics Limited 39
Highland Therapeutics, Inc. 40
Integrative Research Laboratories Sweden AB 41
Intra-Cellular Therapies, Inc. 42
INVENT Pharmaceuticals, Inc. 43
KemPharm, Inc. 44
Luc Therapeutics, Inc. 45
Medgenics, Inc. 46
Merck & Co., Inc. 47
Neos Therapeutics, Inc. 48
NeuroDerm Ltd. 49
Neurovance, Inc. 50
NLS Pharma Group 51
Noven Pharmaceuticals, Inc. 52
P2D Bioscience 53
Polleo Pharma Limited 54
Reviva Pharmaceuticals Inc. 55
Shire Plc 56
Sunovion Pharmaceuticals Inc. 57
Supernus Pharmaceuticals, Inc. 58
Taisho Pharmaceutical Co., Ltd. 59
Taisho Pharmaceutical Holdings Co., Ltd. 60
TRImaran Pharma, Inc. 61
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Combination Products 63
Assessment by Target 64
Assessment by Mechanism of Action 67
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
(nicotine + opipramol hydrochloride) - Drug Profile 74
AR-08 - Drug Profile 75
BCWPE-003 - Drug Profile 76
BLI-1008 - Drug Profile 77
BNC-375 - Drug Profile 78
CB-8411 - Drug Profile 79
centanafadine IR - Drug Profile 80
centanafadine SR - Drug Profile 81
CM-4612 - Drug Profile 84
CTX-1301 - Drug Profile 85
CTX-1302 - Drug Profile 86
dasotraline hydrochloride - Drug Profile 87
dextroamphetamine - Drug Profile 89
dextroamphetamine MR - Drug Profile 90
edivoxetine hydrochloride - Drug Profile 92
Egalet-003 - Drug Profile 94
eltoprazine - Drug Profile 95
etiguanfacine - Drug Profile 100
fasoracetam - Drug Profile 101
guanfacine hydrochloride ER - Drug Profile 103
histamine dihydrochloride - Drug Profile 105
HTL-1071 - Drug Profile 106
INV-107 - Drug Profile 108
INV-170 - Drug Profile 109
IRL-752 - Drug Profile 110
ITI-214 - Drug Profile 111
KP-415 CR - Drug Profile 113
lisdexamfetamine dimesylate - Drug Profile 115
mazindol - Drug Profile 122
Metadoxine ER - Drug Profile 123
methylphenidate hydrochloride ER - Drug Profile 130
methylphenidate hydrochloride MR - Drug Profile 131
methylphenidate hydrochloride SR - Drug Profile 135
methylphenidate hydrochloride XR - Drug Profile 137
MGS-0028 - Drug Profile 139
molindone hydrochloride ER - Drug Profile 140
niacinamide CR - Drug Profile 142
NLS-3 - Drug Profile 143
NLS-4 - Drug Profile 144
NT-0201 - Drug Profile 145
P-001 - Drug Profile 146
PBF-509 - Drug Profile 147
PD-2005 - Drug Profile 148
PD-3044 - Drug Profile 149
PFR-08001 - Drug Profile 150
PFR-8026 - Drug Profile 151
RP-5063 - Drug Profile 152
SHP-465 - Drug Profile 154
Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile 156
Small Molecules for Attention Deficit Hyperactivity Disorder - Drug Profile 157
Small Molecules to Agonize NMDA2D for Attention Deficit Hyperactivity Disorder - Drug Profile 158
Small Molecules to Inhibit Dopamine Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile 159
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 160
Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 161
Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile 162
Small Molecules to Modulate Choline Transporter for ADHD - Drug Profile 163
Synthetic Peptide to Antagonize D2 for ADHD - Drug Profile 164
TS-141 - Drug Profile 165
Vaccine for CNS Disorders - Drug Profile 166
viloxazine hydrochloride ER - Drug Profile 167
vortioxetine hydrobromide - Drug Profile 168
VU-0238429 - Drug Profile 174
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects 175
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products 180
Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones 181
Featured News & Press Releases 181
Appendix 193
Methodology 193
Coverage 193
Secondary Research 193
Primary Research 193
Expert Panel Validation 193
Contact Us 193
Disclaimer 194
List of Tables
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2016 14
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Development, H2 2016 23
Comparative Analysis by Unknown Stage Development, H2 2016 24
Products under Development by Companies, H2 2016 25
Products under Development by Companies, H2 2016 (Contd..1) 26
Products under Development by Companies, H2 2016 (Contd..2) 27
Products under Development by Companies, H2 2016 (Contd..3) 28
Products under Investigation by Universities/Institutes, H2 2016 29
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H2 2016 30
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 31
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV, H2 2016 32
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals, LLC, H2 2016 33
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co. Ltd., H2 2016 34
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioLite, Inc., H2 2016 35
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical, Inc., H2 2016 36
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark, LLC, H2 2016 37
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corporation, H2 2016 38
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Egalet Corporation, H2 2016 39
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company, H2 2016 40
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Ensysce Biosciences Inc., H2 2016 41
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S, H2 2016 42
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Limited, H2 2016 43
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics, Inc., H2 2016 44
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 45
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 46
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 47
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm, Inc., H2 2016 48
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics, Inc., H2 2016 49
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Medgenics, Inc., H2 2016 50
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co., Inc., H2 2016 51
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics, Inc., H2 2016 52
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd., H2 2016 53
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neurovance, Inc., H2 2016 54
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NLS Pharma Group, H2 2016 55
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals, Inc., H2 2016 56
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H2 2016 57
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Polleo Pharma Limited, H2 2016 58
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 59
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H2 2016 60
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 61
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals, Inc., H2 2016 62
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2016 63
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016 64
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by TRImaran Pharma, Inc., H2 2016 65
Assessment by Monotherapy Products, H2 2016 66
Assessment by Combination Products, H2 2016 67
Number of Products by Stage and Target, H2 2016 69
Number of Products by Stage and Mechanism of Action, H2 2016 72
Number of Products by Stage and Route of Administration, H2 2016 75
Number of Products by Stage and Molecule Type, H2 2016 77
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2016 179
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..1), H2 2016 180
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..2), H2 2016 181
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..3), H2 2016 182
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..4), H2 2016 183
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H2 2016 184
List of Figures
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2016 14
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Products, H2 2016 23
Assessment by Monotherapy Products, H2 2016 66
Number of Products by Top 10 Targets, H2 2016 68
Number of Products by Stage and Top 10 Targets, H2 2016 68
Number of Products by Top 10 Mechanism of Actions, H2 2016 71
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 71
Number of Products by Routes of Administration, H2 2016 74
Number of Products by Stage and Routes of Administration, H2 2016 74
Number of Products by Molecule Types, H2 2016 76
Number of Products by Stage and Molecule Types, H2 2016 76
